Logo
Login
$NXGL
$4.26 +$0.29 (7.45%) Close

Company Executives

$NXGL Management Team

Mr. Steven Glassman

Independent Chairman of the Board

Age 60
Compensation $67.88K USD
Sex Male

Mr. Adam Levy

President

Chief Executive Officer

Director

Age 62
Compensation $437.6K USD
Sex Male

Mr. Valter Pinto

Investor Relations

Age -
Compensation -
Sex Male

Mr. Adam Drapczuk

Interim Chief Financial Officer

Principal Financial Officer

Principal Accounting Officer

Age 50
Compensation $248.2K USD
Sex Male

Board of Directors

From the proxy statement filed Jun 9, 2026
Directors
4
serving now
Independent
Not stated
the proxy does not say
Average tenure
2.5 years
from year joined
CEO also chairs the board
No
Steven Glassman
Director Age On board Independent Committees Other public boards 2025 pay Source
Adam Levy
CEO
 63 2021
5 years
 Not stated None stated None stated Paid as CEO
Steven Glassman
Board chair
 61 2021
5 years
 Not stated
Audit Committee Compensation Committee · Chair Nominating and Corporate Governance Committee
None stated $85,883
Brian J. Kieser
59 2026
0 years
 Not stated None stated None stated Not stated
Kevin M. Harris
51 2026
0 years
 Not stated None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

5 disclosed in the proxy filed Jun 9, 2026
Sequence LifeScience, Inc.
Indirect sole owner is Brian J. Kieser, our Chief Executive Officer and a director appointed May 6, 2026
$5,500,000

Sequence purchased April Notes and April Warrants in the April 2026 Financing

Open in proxy
Three members of our Board and two executive officers
Directors and executive officers of the Company
$125,000

Directors and executive officers invested in the April 2026 Financing on the same terms as unaffiliated Buyers

Open in proxy
Brian J. Kieser
Director appointed to our Board on May 6, 2026
$1,000,000
Between May 11, 2026 and May 14, 2026

Mr. Kieser purchased May Notes and May Warrants in the May 2026 Financing

Open in proxy
Mr. Levy
Director of the Company
$60,000
Between May 11, 2026 and May 14, 2026

Mr. Levy purchased May Notes and May Warrants in the May 2026 Financing

Open in proxy
Mr. Henry
Director of the Company
$25,000
Between May 11, 2026 and May 14, 2026

Mr. Henry purchased May Notes and May Warrants in the May 2026 Financing

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans